Loading BioAtlas...
Loading BioAtlas...
将生物大模型、对接计算引擎与组学管线并排横向对比。按获取方式、硬件开销及细分领域灵活筛选，在一分钟内得出客观可辩护的技术选型方案。
| 技术参数指标 | ＋ 添加工具 | |
|---|---|---|
| Category | Drug Discovery & Chemistry | — |
| Subcategory | End-to-End AI Drug Discovery Platform | — |
| Company | Insilico Medicine | — |
| Access mode | Commercial Subscription & Co-Development | — |
| Licence conditions | Proprietary commercial software | — |
| Compute requirements | Cloud SaaS with enterprise security compliance | — |
| Biological application | Fibrosis, oncology, immunology, and age-related disease drug discovery | — |
| Research workflow | Disease multi-omics data -> novel target selection -> generative chemistry -> candidate synthesis | — |
| Evidence level | Clinical-stage pipeline with published experimental and clinical validation (Nature Biotech 2024) | — |
| Commercial eligibility | Commercial enterprise licensing and drug discovery partnerships | — |
| Price | Enterprise partnership — contact vendor | — |
| Availability ⓘ | Globally available for biopharma partners | — |
| Features | PandaOmics for multi-omics target identification and biological aging biomarker analysis, Chemistry42 generative chemistry platform with 42 distinct generative algorithms, Demonstrated progression of novel targets and molecules into Phase II clinical trials (e.g. ISM001-055 for IPF), High-throughput synthetic accessibility and automated ADMET filtering | — |
| Entry type | Commercial Platform | — |
| AI role | End-to-End Generative Chemistry | — |
| Input data | 未明确记录 | — |
| Output data | 未明确记录 | — |
| Validation | 未明确记录 | — |
| Type | End-to-end generative AI drug platform | — |
| Intended use | 未明确记录 | — |
| Compatibility | 未明确记录 | — |
| Manufacturer | Insilico Medicine | — |
| Integration evidence | https://insilico.com/platform | — |
| Laboratory handoff | Compounds synthesized in automated robotic labs for biochemical IC50 testing | — |